This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis

This study has been completed.
Information provided by (Responsible Party):
Promius Pharma, LLC Identifier:
First received: January 21, 2009
Last updated: December 1, 2016
Last verified: December 2016
This study compares the effectiveness of two topical creams for atopic dermatitis in pediatric subjects. Subjects will be randomly assigned to use one of the two creams twice daily for 6 weeks or until clear.

Condition Intervention Phase
Atopic Dermatitis Device: EpiCeram Skin Barrier Emulsion Drug: Desonide Cream 0.05% Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Investigator-Blind, Six-Week, Parallel Group, Multicenter Pilot Study to Compare the Safety and Efficacy of EpiCeram Skin Barrier Emulsion and Desonide Cream 0.05% in the Twice Daily Treatment of Pediatric Subjects With Moderate Atopic Dermatitis

Resource links provided by NLM:

Further study details as provided by Promius Pharma, LLC:

Primary Outcome Measures:
  • Change From Baseline in Three Item Severity Score [ Time Frame: Baseline to 6 weeks ]
    The average of the sum of scores for erythema, edema/papulation, and excoriation for two target lesions. Scoring on a scale of 0 to 3 (none to severe). Maximum score is 9.

Enrollment: 100
Study Start Date: March 2009
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
EpiCeram Skin Barrier Emulsion
Device: EpiCeram Skin Barrier Emulsion
topical cream, twice daily, 6 weeks
Active Comparator: 2
Desonide Cream 0.05%
Drug: Desonide Cream 0.05%
topical cream, twice daily, 6 weeks


Ages Eligible for Study:   3 Months to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • at least 3 months of age and less than 13 years of age
  • atopic dermatitis of moderate severity

Exclusion Criteria:

  • pregnant or lactating
  • treatment of atopic dermatitis with topical product in the 14 days prior to Baseline
  • treatment of atopic dermatitis with systemic product in the 30 days prior to Baseline
  • serious or uncontrolled medical condition
  • active infection
  • significant use of inhaled, intranasal, or intraocular corticosteroid
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00828412

United States, Colorado
National Jewish Health
Denver, Colorado, United States, 80206
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, North Carolina
Wake Forest University Health Sciences
Winston Salem, North Carolina, United States, 27157
United States, Ohio
Dermatology Research Associates
Cincinnati, Ohio, United States, 45230
United States, Texas
University of Texas
Houston, Texas, United States, 77030
Sponsors and Collaborators
Promius Pharma, LLC
Study Director: Joanne Fraser, PhD Promius Pharma, LLC
  More Information

Responsible Party: Promius Pharma, LLC Identifier: NCT00828412     History of Changes
Other Study ID Numbers: EPC0801
Study First Received: January 21, 2009
Results First Received: September 17, 2013
Last Updated: December 1, 2016

Additional relevant MeSH terms:
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases
Decanoic acid
Antifungal Agents
Anti-Infective Agents
Anti-Inflammatory Agents
Dermatologic Agents processed this record on August 23, 2017